First Patient Dosed in Sleep Apnea Pill Second Phase 2 Clinical Trial
A total of 30 participants will be enrolled. Each participant will receive two different dose levels of AD109, and placebo, at bedtime.
Category: Emerging Compounds
Emerging Compounds
Latest
Emerging Compounds
Latest
FDA Fast Tracks Xywav for Idiopathic Hypersomnia
"There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person's daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time."
Emerging Compounds
PopularJazz Pharmaceuticals Trials Lower Sodium Alternative to Xyrem
Jazz Pharmaceuticals plc announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an investigational oxybate product candidate with 90% less sodium content than Xyrem (sodium oxybate)...
Imbrium Therapeutics Phase 1b Trial Reports Better Sleep Efficiency & Lower WASO
IMB-115 is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor.
Read MoreAxsome’s Investigational Narcolepsy Compound Gets FDA Breakthrough Therapy Designation
The Breakthrough Therapy designation for AXS-12 was supported by the positive results from the Phase 2 CONCERT study.
Read MoreAvadel Shares Additional Data from Phase 3 Trial of Potential Narcolepsy Drug
“We are at a pivotal point in Avadel’s transformation, as we recently completed our pre-NDA meeting with the FDA and are currently focused on completing our NDA submission and filing for FT218.”
Read MorePhase 3 Study Results of Investigational Dual Orexin Receptor Antagonist for Insomnia to Be Presented at SLEEP 2020
Idorsia Ltd reports positive results from the first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin receptor antagonist, daridorexant, in adult and elderly patients with insomnia.
Read MoreFDA Grants Priority Review Vanda’s for Melatonin Receptor Agonist HETLIOZ (Tasimelteon) for Smith-Magenis Syndrome
HETLIOZ (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome in a placebo-controlled clinical study.
Read MoreIntranasal Leptin Prevents Opioid-Induced Sleep Apnea in Obese Mice
When on opioids, people with sleep apnea are likely to have more breathing pauses than those who are not medicated.
Read MoreFirst Patient Dosed in Open-Label Extension/Switch Study of Investigational Narcolepsy Treatment
The study will enroll about 250 patients at most of the North American clinical trial sites that participated in the REST-ON study.
Read MoreAvadel Sells Off Sterile Injectable Drug Portfolio to Focus on Investigational Narcolepsy Drug Formulation
The sale of the sterile injectable drug portfolio is a significant milestone for the company, as it reflects a commitment to strategically focus on advancing FT218.
Read More
What Is Serotonin’s Role in Obstructive Sleep Apnea?
Researchers demonstrated that the neurotransmitter serotonin plays a critical role in rousing the brain from sleep when CO2 levels rise.
Read MoreWith its potential to improve memory functions in a variety of disorders, ACD856 can play a significant role in treating indications where these key functions are impaired, such as...sleep apnea.
Johan Sandin, chief scientific officer at AlzeCure Pharma
An Investigational Tetanus Toxin-Based Sleep-Disordered Breathing Therapy Is In the Works
An investigational CPAP alternative that uses tetanus toxin molecules to potentially treat sleep-disordered breathing is being unveiled at a global biotech innovation event this week.
Read MoreMedicinal Cannabis Clinical Trial Shows Insomnia Symptom Improvement
Its findings suggest that ZTL-101 cannabis treatment is safe and effective for chronic insomnia.
Read MoreTherapix Biosciences Closes Joint Venture Transaction for Sleep Indication
Therapix Biosciences has closed a joint venture transaction for collaboration in the field of developing pharmaceuticals for a sleep-related indication.
Read MoreTokyo-Based Company Makes Scientific Progress with Orexin Agonist Program
Tokyo-based Sosei Group Corp has made further progress with its orexin program, which is being developed in conjunction with its spin-off companies Orexia Ltd and Inexia Ltd.
Read MoreRespireRx Appoints President/CEO
RespireRx Pharmaceuticals Inc, which is developing dronabinol for the treatment of obstructive sleep apnea, announces that Timothy Jones has joined as its president and CEO.
Read More